Member Info for Brondby

Https://twitter.com/CizzlePlc/status/1757339538978947133

"The tests will be cost-effective to produce and simple to use."

I think they are trying to tell us something ...

Techtonic, yes its been retesting the 200dma and held well so far. SP hasn't dropped as much as last cycle and the oscillator indicators are now beginning to swing in our favour. So could go back up later this week or next. Don't necessarily agree with a drop as the alternative, as the 2p+ level now look strong and we must be just days/weeks from news. Imagine how you'd feel if you sold now, having held so long, and woke up to a Biotechne buy out. So ranging just above 2p would seem the alternative (to me). If it does drop, I'm buying more! In for a penny...

As you say, a bit irrelevant for those here for the big RNS. I believe in this technology. It has years of research behind it and major progress made in overcoming obstacles made over the last year. There may be bumps along the way, but I'm confident it will get to market, and it will be worth a whole lot more than £8.5M!!

For me, its the market cap that does it. If this were a £30M cap company you'd have more risk.

But at £8m cap, with a year cash runway in shares, an agreed £0.5m loan facility if needed, major global partners, and a biotech market in recovery, they don't come lower risk to high reward than this!

DYOR obviously! I'm sure you all will.

Techtonic, 20p to 40p would be great for anyone entering at current levels.

But i think the bigger vauations are coming on the basis that the major investors 2.5 years ago didn't risk their millions for a x2 or x4 return!

The global market for this is huge.

US biotech fundraising boom ends two-year deal drought

https://www.ft.com/content/5c45f23b-9b43-4a95-8dcc-44587317b0dd

... working together on this and will run a formal trial when they believe the necessary specificity/accuaracy will be reached.

It could of course aldo be better, having removed manual variables from the process.

The point being, there is little point in an update until we know those numbers. Its also unlikely to be a " run trial and report accuracy" type of set up. They will be working to

VV, for all we know, they have sold some CDT. I don't believe they would need to tell us until financial statments, as we are not an investment company divesting of an investment. These are just liquid funds available to us. Would be a brave CEO to raise funds when we have a £1m-£2.5 liquid asset (range based on last few months of share price movement).

My own guess is we may see a number of important commercials in the coming months. Perhaps investment in ciz from Biotechne, or another, connected to development of the point of care test, or to LDT within other countries.

Hi VV,

My point, perhaps not as well made as it could have been, was more about not needing cash until after trials are over and LDT is launched, at which point we are in a very strong position, with revenue on the horizon.

And of course if CDT does eventually fly in the coming months (my $3 baseline is a relatively low bar, its been as high as $7 and a long while around $5), or if we get revenue from the LDT more quickly, or if we cut a deal with BioTechne, etc. then its possible no further raise is necessary at all.

My own hope is that we will be bought out before we need a further raise.

CDT up 18% today at $3.25. May be about to do another run. Keep a close eye as its certainly looked stronger last few days.

A reminder that even at just $3, ciz's 395k shares are worth £936k and would fund over 13 months activity at the £70k monthly burn rate Charles Archer estimated in his report back in Sepember. At that point they had cash until Dec 2023.

So, in my view ciz is well funded (fantastic position in this market) and Allan Syms has previosuly stated they are funded until end of 2024.

Assuming our LDT test is out first hald of this year, we should have revenues flowing before we run out of cash. That's before any potential deal with BioTechne.

Looks rosy in my view, provided automated test has similar results to prototype, and j think cizzle would not have moved to clinical trials without some degree of confidence around this.

TechT, I suspect you just do your levels to a higher degree of detail than me!

I'm not really a trader, so I don't draw lines on charts or calculate precise levels.

Call me a physicist, to your mathematician 😀

I just look at charts and approximate levels by eye.

So to my eye, ciz is in a weak uptrend, fairly strong support at (approx) 2.35p. Needs to break past 2.5p, and i think it can do so on the next cycle. We'll see.

TechT, on the technicals, i'd saybCDT was still in uptrend on 20th Dec when i made the comment, but did lose that a few days later when it started to range just under 5p, and then later again started a fall. You'll find some of my comments on CDT on Vela board.

I think all price action is driven by technicals to some extent. Every churn of shares at a level is bringing a new set of buyers in at a price, below which they would need to sell at a loss. The 2.35p 6 month point of control support is looking quite strong now, as we saw today. (Volume today actually looks to be in the top 10 of the last 3 months)

So I'm sticking with ciz being in an uptrend, albeit a weak one, on that we agree, and we'll see a rise again next week.

Of course, news trumps technicals! And i cant predict when that will come!

TechT,

Charles Archer estimated based on last accounts and run rate that we had cash until December. We're well past that now, and would have needed to secure (and hence announce) new funds well in advance of running out. So my assumption is we've been selling CDT. Would be quite sensible IMO, as

a) value of CDT is completely out of our hands, so we should use it as a source of funds for things we do control

b) any raise after a successful LDT is announced (and i think ciz are very confident of success) would be at multiples of current sp. (We already know they have funds available at 2.1p) and we might not need any funds if they can do a deal with Biotechne.

All my own speculation.

The chart looks to be on an uptrend TechT.

Currently on a pullback and bounced off the 200 dma today. Oscillators should turn soon in its favour, IMO.

I think they will avoid any raise. Just keep drip selling CDT. If there is any raise for future acceleration, i think it will be announced simultaneously with good news,

when it will be done at multiples higher.

I almost feel sorry the seller today, possibly had their shares prised away by some stop losses, albeit now in the good hands of neilin62 :-)

I never use automatic stop losses. MMs will just drop the big to fill an order. I mean 2.1 it was showing at earlier FFS. Folks are paying 2.58 the other day and MMs are trying to grab shares at 2.1.

In a share like ciz, we are basicially waiting for the LDT news, so why on earth sell before that news!

More weak hands removed.

Setting up for a move north.

It will move up before news IMO. Unless of course we continue to have 20k sellers exiting! 6 month and 3 month point of control is around 2.35p and is much stronger. 1 year POC is over 3p. Shares are hard to come by (can sell now for over midprice) so just a little more buying pressure will see a rise.

Every day without news is a day closer to news, so id say we will get more buying pressure.

And I'd say most folk still here are here for the news, potentially transformational news, which should limit selling.

Oapk20, I think next week for a move up, based purely on momentum indicators. But could be earlier.

I note again your comment yesterday about pumping. In my view what is remarkable here is just how little pumping there is!! Just quiet, patient, waiting. No hype. Just getting on with the job. News when its worthwhile. That, in my mind is one of the plus sides of this share.

And despite no pumping, sp is holding up well.

Where was the pumping?

I'm fairly relaxed about someone else selling their golden ticket. Further consolidation at a higher level builds a nice base 👍

And if there is a raise tomorrow am, should be easy to find the insider trader. 👮‍♂️🚔🔒

I don't think we are really competing with what BioNTech are doing, other than us both working on things related to cancer.

I think ciz will ramp up publicity hugely once we have a product in market. We can shout all we like just now, but until we have a product out there, its all still "potential".

I also don't think large biotechs will need to be told the significance of the ciz test if as successful on the high throughout automated platform as it was in earlier lab trials.

If there is any hint that we have cracked the LFT style point of care test (I dont know enough about what the obstacles are here) then we are really goinf to be flying.

Of what relevance do you think thia is bearsandbulls?

I can't see the Telegraph article but suspect its just a follow on from this announcement last July:

https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials

As far as i can see, its taking *existing* cancer patients and applying immunotherapy, essentially personalised treatment/vaccines.

So treatement, not a generic preventative cancer vaccine for all, or anything related to diagnostics?

So I'm stuggling to see the relevance. Am I missing something?

I agree with Greend100 that ciz are unlikely to announce trial has started. Its not really substantive news IMO, as they've told us what they intend to do in previous RNS's.

They have never given running commentary on operational work, and have tended to announce milestones or achievements when complete.

Lots of possible news on many fronts, but nobody can say when for sure. Allan was hinting at progess on the LFT back in the August interview, which was nearly 6 months ago, and on additional cancers.

So I think there will be news in several areas in the coming weeks and months.

I'm rather hoping that Allan is too busy to prepare and release fluff RNS's due to negotiating large deals! But of course, time will tell.

VincentVega,

Going on the RNS 10th August 2023:

"The next steps are to finalise standard production and operating protocols and to commence clinical trials that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA. The Company will then extend that to other key markets and will extend its use through regulatory approval with the FDA in the USA, the EMA for a CE mark in Europe, the MHRA in the UK for UKCA approval, and with the appropriate regulatory groups elsewhere in the world including China. "

Allan has said in the past the NHS is well aware of our test, and have tweeted previosuly about how their blood test could complement the screening programme. I think it would count as an in vitro medical device, requiring MHRA approval.

Of course, if the point of care LFT style test is further progressed than we know, that may be a more effective route to market.

Just feels like ciz have a lot more up their sleeve to tell us about from what Allan has said in the past, but they know biotech takes a while, so are avoiding carrot dangling - instead waiting for significant advances before RNSing.